Opinion|Videos|April 11, 2025

Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11

Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 2–11, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.

Episodes in this series

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

  • If approved for use in ages 2-11, how do you see ruxolitinib cream fitting into the treatment landscape for pediatric atopic dermatitis?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME